Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Deep Transcranial Magnetic Stimulation · 1 trial · 1 indication
Response to treatment is defined as a ≥ 50% reduction in the scores of the HAM-D21. Remission is defined as a HAM-D21 score ≤ 9.
| Name | Type | Description |
|---|---|---|
| Deep Transcranial Magnetic Stimulation (DTMS) | DEVICE | DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold. |
Inclusion Criteria: * Presence of a current major depressive disorder (according to the DSM-IV-TR) that has not improved after ≥ 1 but ≤ 5 adequate antidepressant trial(s) in the current episode * Baseline score ≥ 15 on the QIDS-C * Stable medication regimen (\> 4 weeks) Exclusion Criteria: * Psy...
Top 20 of 29 competitors
Deep Transcranial Magnetic Stimulation is an investigational therapy being studied for the treatment of Major Depressive Disorder. It is a non-invasive psychiatric intervention that is currently in clinical development, with one completed Phase 2 trial evaluating its effectiveness in patients with this condition.
Deep Transcranial Magnetic Stimulation is being developed by BrainsWay Ltd., a company traded under the ticker BWAY. The company is conducting clinical research to evaluate the therapy's potential in treating Major Depressive Disorder.
Deep Transcranial Magnetic Stimulation is in Phase 2 of clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities and is still being studied for safety and effectiveness in treating Major Depressive Disorder.
Deep Transcranial Magnetic Stimulation has one completed clinical trial, identified as NCT01409304, titled 'Effectiveness of Deep Transcranial Magnetic Stimulation in Depression.' This Phase 2 study enrolled 18 participants with Major Depressive Disorder and was conducted in Canada.
Deep Transcranial Magnetic Stimulation is not FDA approved. It is an investigational therapy currently in Phase 2 clinical development for Major Depressive Disorder. The therapy has completed one clinical trial, but it has not yet received regulatory approval for commercial use.